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Abstract RNA interference (RNAi) provides a powerful tool to
silence genes in a sequence-speci¢c manner in a variety of sys-
tems. However, not all sequences are e¡ective in the RNAi-
mediated gene silencing. In this study, we developed a polymer-
ase chain reaction (PCR)-based RNAi strategy for a quick
screening of small interfering RNA (siRNA) e⁄ciency. This
method utilized a two-step PCR to generate a chimeric DNA
template containing the U6 promoter or cytomegalovirus pro-
moter and short hairpin DNA. We demonstrated that the trans-
fection of the PCR products into mammalian cells resulted in
speci¢c depressions of exogenous (luciferase, green £uorescent
protein and L-galactosidase) and endogenous (annexin II) gene
expressions. This PCR strategy provides a rapid, easy and
cheap approach for testing candidates siRNA sequences and is
an attractive alternative to subcloning.
/ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
One of the most frequently asked questions in biological
research is what is the function of a particular gene product.
A direct approach for answering the question is the loss-of-
function study. In mice, gene knock-out is widely used, but it
is time-consuming and costly. Other methods such as anti-
sense oligonucleotides and dominant-negative have limited
success because of insu⁄ciency and inconsistency. Recently,
a rapidly developed technique, RNA interference (RNAi), has
been showing great promise in depressing gene expression in a
variety of systems including Caenorhabditis elegans, Drosophi-
la, fungi, plants and animals [1]. RNAi is a process of se-
quence-speci¢c post-transcriptional gene silencing via dou-
ble-stranded RNA (dsRNA). It is believed to have evolved
as a host defense mechanism directed at transposable elements
and infecting viruses. Naturally occurring RNAi proceeds via
a two-step mechanism. In the ¢rst step, long dsRNAs are
recognized by a nuclease in the RNase III family known as
Dicer, which cleaves long dsRNA into double-strand frag-
ments between 21 and 23 nt in length, termed small interfering
RNA (siRNA). These siRNAs are incorporated into the
RNA-induced silencing complex, which recognizes and cleaves
the corresponding mRNA. Introduction of 21-nt RNA du-
plexes into mammalian cells leads to speci¢c depression of
target genes without triggering interferon responses [2,3].
This discovery signi¢cantly advances the ¢eld and provides
a powerful tool for studying protein functions. Since then,
RNAi has been applied to many di¡erent cell cultures includ-
ing mammalian cells [2^4], primary cell culture [5^7], embry-
onic stem cells [8,9], and animals [10^14].
To knock down target genes in mammalian cells, chemically
synthesized 21-nt siRNA duplexes were ¢rst used [2,3]. siRNA
can also be in vitro transcribed with T7 RNA polymerase, and
such siRNA was as e¡ective as chemically synthesized siRNA
[15,16]. To obtain stable transfection in cells and animals,
DNA expression vector-based siRNA has been developed.
In this strategy, a short hairpin RNA (shRNA) or antisense
and sense RNAs are generated in cells under the control of an
RNA polymerase II (cytomegalovirus, CMV) [11,17] or III
(U6 or H1) promoter [15,18^22]. To increase transfection ef-
¢ciency or integrate shDNA into the genome, a retroviral or
lentiviral vector-based siRNA has been used [7,11,23^27].
Much progress has been made in perfecting the RNAi tech-
nique in a short period of time. However, the e⁄ciency of
siRNA is dependent on the identi¢cation of speci¢c target
sites because not all sequences are e¡ective in RNAi-mediated
gene silencing. To date, choosing of siRNA sequences is still
empirical although a few rules can be followed. Generally,
several siRNAs derived from di¡erent regions of a target
mRNA need to be tested in order to achieve an e⁄cient si-
RNA, which is costly and time-consuming. Therefore, a quick
and easy method to obtain siRNAs for the screening of e⁄-
ciency is warranted. In the current study, we described a poly-
merase chain reaction (PCR)-based shRNA strategy that elim-
inates the requirement to subclone the U6^shDNA cassette
into an expression vector. The siRNA expression cassette is
formed by two-step PCR from a plasmid-encoded U6 pro-
moter as the template. The transfection of U6^shDNA PCR
products into mammalian cells speci¢cally depressed expres-
sion of exogenous and endogenous genes. Furthermore, the
replacement of U6 promoter with CMV promoter had a sim-
ilar result in gene silencing.
2. Materials and methods
2.1. Target sites for silencing gene expression
Fire£y luciferase (pGL3), green £uorescent protein (GFP), L-galac-
tosidase (LacZ) and an endogenous gene, annexin II, were used to test
the e⁄ciency of gene silencing by PCR products, which contain the
U6 or CMV promoter and the corresponding targeted sequences. The
sequences corresponding to target sites are as follows: coding regions
153^173 (5P-AACTTACGCTGAGTACTTCGA-3P) for pGL3; 104^
127 (5P-AAGGTGATGCTACATACGGAAAGC-3P) for GFP; 427^
447 (5P-AACTCGGCGTTTCATCTGTGG-3P) for LacZ; 495^495
(5P-AAGGACATCATCTCTGACACA-3P) or 876^896 (5P-AATCA-
TGGTCTCTCGCAGTGA-3P) for mouse annexin II. Some of these
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sequences have been tested by other investigators using di¡erent meth-
ods and were e¡ective in silencing gene expression [2,28].
2.2. Preparation of PCR products containing U6 promoter and shDNA
Using ApaI-digested plasmid pSilence1.0-U6 (Ambion) as a tem-
plate, U6 promoter followed by a 19^22-nt sense strand of siRNA,
a 9-nt loop (5P-TTCAAGAGA-3P), a 19^22-nt antisense strand of
siRNA, and a stretch of six deoxythymidines (poly(T)6) were ampli-
¢ed by two-step PCR. The forward primer, 5P PU6F (5P-CACC-
GAATTGGGTACCCGCTC-3P), is complementary to the 18 nt at
the 5P-end of the U6 promoter and was used for all PCR steps.
5P PU6F contains four nucleotides, CACC, which will enable direc-
tional cloning of PCR products into adenovirus expression systems in
future. In the ¢rst round of PCR, the reverse primer, 3P Primer 1
consisted of (5P) the 9-nt loop, a 19^22-nt antisense sequence and
GGCC (3P). The reaction conditions were 95‡C, 3 min; 95‡C for
30 s, 60‡C for 40 s, 72‡C for 40 s, 35 cycles; 72‡C, 10 min. One
microliter of this ¢rst PCR reaction mixture was re-ampli¢ed in the
second round of PCR reaction using the same forward primer 5P PU6F
and a new designed reverse primer, 3P Primer 2, which contains (5P)
poly(A)6, a 19^22-nt sense strand of siRNA, and a complementary
sequence to the 9-nt loop (3P). The optimal annealing temperature was
increased to 62‡C, 40 s. The PCR products were puri¢ed using QIA-
quick PCR puri¢cation kit (Qiagen).
2.3. Preparation of PCR products containing CMV promoter and
shDNA
The CMV promoter was ampli¢ed using the plasmid pcDNA3.1/
CT-GFP (Invitrogen) as a template by a CMV forward primer,
5P PCMVF (5P-CACCGATGTACGGGCCAGATATACG-3P), and a
reverse primer complementary to the 3P-end of the CMV promoter
(5P-TCTCTTGAAGGGCCCTAGTTAGCCAGAGAGCTCTGC-3P).
The ApaI restriction site (GGGCCC) was added at the 5P-end of the
reverse primer. After digestion of the CMV promoter with ApaI,
we used the same two-step PCR as described above to make the
PCR products containing CMV promoter and shDNA except that
5P PCMVF was used as the forward primer. To generate the PCR
products containing the CMV promoter and a sense or an antisense
strand of siRNA, one-step PCR was performed using the CMV for-
ward primer 5P PCMVF and the reverse primer containing the antisense
or sense sequence and a complementary sequence (5P-AGTTAGCCA-
GAG-3P) to the last 12 nt of the CMV promoter (3P primer A or
3P primer B). The PCR conditions were as follows: 30 s at 95‡C,
30 s at 58‡C, 45 s at 72‡C for 35 cycles.
2.4. Cell culture and transfection
NIH/3T3 and L-2 cells, and 293A cells were purchased from ATCC
and Invitrogen, respectively. L929 cells were a generous gift from Dr.
R. Eberle (Oklahoma State University). NIH/3T3, 293A, and L929
cells were cultured in Dulbecco’s modi¢ed Eagle’s medium containing
25 mM glucose, 44 mM NaHCO3 and 10% fetal bovine serum (FBS).
L-2 cells were maintained in F-12K medium (ATCC) supplemented
with 10% FBS. Cells were cultured in a humidi¢ed atmosphere con-
taining 5% CO2 at 37‡C. All media were supplemented with penicillin
(100 U/ml) and streptomycin (100 Wg/ml). FBS was heat-inactivated.
Twenty-four hours before transfection, the cells at 50^80% con£uence
were trypsinized, diluted 1:5 with fresh medium without antibiotics
(1^3U105/ml), and transferred to 24-well plates (500 Wl/well). Report-
er gene plasmids, pcDNA3.1/CT-GFP and pLenti6/V5-GW/LacZ,
and pGL3 and pRL were obtained from Invitrogen and Promega,
respectively. Co-transfection of 0.5 Wg of reporter gene plasmids and
0.3 Wg of PCR products was carried out with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. After trans-
fection, the cells were incubated for 24 h for reporter gene expression
and for 48 h for endogenous gene expression. Luciferase expression
was subsequently monitored with the dual luciferase assay (Promega).
To detect the expression of the LacZ gene, the ¢xed cells were incu-
bated at 37‡C overnight with 5-bromo-4-chloro-3-indolyl-L-D-galacto-
pyranoside (X-gal) at pH 8.2. Staining for X-gal at this pH gave no
non-speci¢c staining in the control culture. The expression of GFP
was directly detected by an inverted £uorescence microscope or West-
ern blot.
2.5. Western blot
The cells were harvested and lysed with the lysis bu¡er (250 mM
sucrose, 1% Triton X-100, 10 mM EGTA, 2 mM EDTA, 50 mM
Tris^HCl, pH 7.4, 200 Wg/ml leupeptin, and 1 mM phenylmethylsul-
fonyl £uoride, pH 7.4). The cell lysate (10^20 Wg protein) was sepa-
rated by sodium dodecyl sulfate^polyacrylamide gel electrophoresis
and electrophoretically transferred onto a polyvinylidene di£uoride
membrane (Millipore, Bedford, MA, USA). After blocking non-spe-
ci¢c binding sites with 5% non-fat milk, the membrane was incubated
with primary antibodies for 1 h at room temperature. The primary
antibodies used in this experiment were as follows: anti-GFP anti-
body (BD Biosciences, 1:1000 dilution) and anti-annexin II polyclonal
antibody (Santa Cruz Biotechnology, 1:3000 dilution). After washing,
the blot was incubated with horseradish peroxidase-conjugated anti-
mouse or anti-rabbit IgG, and immunoreactive bands were visualized
with the ECL kit (Amersham Biosciences).
3. Results and discussion
3.1. Design of U6^shDNA PCR products
siRNA can be synthesized in cells using expression vectors
containing a short hairpin structure (shDNA) and a RNA
polymerase II (CMV) [11,17] or III (U6 or H1 promoter
[7,15,18^22]. Although the process can yield large quantities
of plasmids, it is time- and labor-intensive, especially when
several siRNA designs need to be tested. Since PCR is in
routine use in most of the biomedical research laboratories,
and is relatively faster than constructing vectors, we attempted
to make a DNA template containing U6 promoter and
shDNA by PCR for in vivo synthesis of siRNA in cells.
Fig. 1. Schematic representation of the PCR strategy used to yield PCR-based siRNA expression cassettes. Two-step PCR. The ¢rst PCR am-
pli¢ed U6 promoter^sense strand^loop (7 nt) using primer pairs 5P PU6F and 3P Primer 1 (5P loop^antisense strand^GGCC 3P). The second
PCR ampli¢ed U6^promoter^sense strand^loop^antisense strand^poly(T)6 using primer pairs 5P PU6F and 3P Primer 2 (5P poly(A)6^sense
strand^the 7-nt loop 3P). The ¢nal PCR products consisted of U6 promoter, shDNA and terminator sequence, six thymidines (T6).
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This was accomplished by two rounds of PCR as shown in
Fig. 1. We ¢rst digested pSilencer1 1.0-U6 plasmid with ApaI
to generate a GGCC overhang at the 3P-end of the U6 pro-
moter. The ¢rst round of PCR was performed using a forward
primer, 5P PU6F, derived from the very beginning of the U6
promoter and a reverse primer, 3P Primer 1, containing (5P) a
loop sequence (9 nt), an antisense strand of siRNA and four
base GGCC (3P), which is complementary to the ApaI-di-
gested overhang at the 3P-end of the U6 promoter. In the
second round of PCR, we used the same forward primer
and a new reverse primer, 3P Primer 2, containing (5P) a
stretch of six deoxyadenosines (A6), a sense strand of siRNA,
and a sequence complementary to the 9-nt loop sequence (3P).
The ¢nal PCR products (U6^shDNA) contain U6 promoter,
sense, loop, antisense and a terminator (T6) sequence. These
PCR products were puri¢ed before use. Our design for the
U6^shDNA PCR products has the following features. (i) The
forward primer 5P PU6F is universal and can be used for all
target genes. (ii) In the ¢rst round of PCR, we only used a
4-nt GGCC at the 3P-end of the reverse primer to complement
the 3P overhang of the U6 promoter generated by ApaI. In
this case, the annealing temperature can be increased to 60‡C
in order to obtain a single-band PCR product. (iii) All primers
used in the PCR reactions are relatively short (9 34 nt). This
reduces errors that can occur during the synthesis of long
primers (s 40 nt). Our initial design utilized a one-step
PCR reaction using the forward primer 5P PU6F and a long
reverse primer (61 nt) that harbors (5P) terminator, sense,
loop, antisense and GGCC. However, we found that more
than 70% of inserts have mutations after cloning the PCR
Fig. 2. Inhibition of exogenous genes by U6^shDNA PCR products. A: Sequence and putative folding of short hairpin oligonucleotides used
to target the pGL3, GFP and LacZ genes. The 19^22-nt sequence of the target transcript separated by a short spacer (shown as a loop) from
the reverse complement of the same sequence is shown. The termination sequence consists of six thymidines (T6). In U6^shGFPm and U6^
shLacZm, two-base mismatches only occur in the antisense strands (shown in bold). B: Dual luciferase reporter system: U6^shGL3 PCR prod-
ucts were co-transfected for 24 h with pGL3 and pRL plasmids into L929 cells. pGL3 activity was normalized by pRL. For comparison,
chemically synthesized siRNA duplexes (GL3^si) and a shGL3 U6 plasmid (pU6^shGL3) were included. The target sequence for pGL3 is the
same. pUC18 plasmid was used as a control. C,D: The PCR products, U6^shGFP or a mutated form (U6^shGFPm), were co-transfected for
24 h with a GFP plasmid into L929 cells. GFP expression was detected by Western blot (C) or a £uorescence microscope (D). U6^shLacZ
PCR products were used as a control. In the Western blot, L-actin was used as a loading control. E: The PCR products, U6^shLacZ or a mu-
tated form (U6^shLacZm), were co-transfected for 24 h with a LacZ plasmid into L929 cells. LacZ was detected by staining with X-gal. U6^
shGFP PCR products were used a control.
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products into a plasmid. These mutations were due to the
synthesis of the long primer because all of those mutations
were located at the 3P-end of the reverse primer. We therefore
chose a two-step PCR to synthesize the sense and antisense
strands separately and to link the two strands by inserting the
complementary 9-nt loop sequence into each strand. (iv) To
avoid the synthesis of long primers, we did not incorporate
any other restriction sites into the PCR products, except four
bases (CACC) at the 5P-end of the forward primer. Thus, we
can clone the ¢nal selected PCR products into expression
vectors through Topo directional TA cloning after testing
their e⁄ciency.
3.2. E⁄cient inhibition of both exogenous and endogenous
genes by U6^shDNA PCR products
To determine whether this PCR-based approach can be
used to inhibit exogenous gene expression in mammalian cells,
we used a dual luciferase reporter system [2]. In this system,
¢re£y luciferase plasmid (pGL3) and sea pansy luciferase plas-
mid (pRL) were co-transfected into L929 cells (mouse ¢bro-
blast) along with U6^shGL3 PCR products, which are pre-
dicted to synthesize siRNA targeting to the ¢re£y luciferase
mRNA (Fig. 2A). Silencing of pGL3 by the U6^shGL3 prod-
ucts was then determined by the amount of reduction of
pGL3 activity after normalization with pRL activity to keep
the transfection e⁄ciency at the same level. As shown in Fig.
2B, the U6^shGL3 PCR products reduced pGL3 activity by
95%. The depression of pGL3 gene expression is comparable
to the chemically synthesized 21-nt siRNA duplexes (GL3^si)
or a U6 plasmid containing the same shDNA (pU6^shGL3).
A similar result was obtained in NIH/3T3 cells (mouse ¢bro-
blast) and L-2 cells (rat lung epithelial cells) (data not shown).
We next tested other two reporter genes, GFP and LacZ,
using the PCR-based RNAi strategy (Fig. 2A). The U6^
shDNA PCR product targeted to GFP (U6^shGFP) was co-
transfected with pcDNA3.1/CT^GFP plasmid into L929 cells,
and Western blot was used to detect GFP protein. After nor-
malizing to L-actin, GFP expression in the U6^shGFP-trans-
fected cells was reduced to 8.5% of the control cells (U6^
shLacZ-transfected cells) as determined by densitometry.
However, a two-base mismatch (U6^shGFPm) only slightly
a¡ected the GFP expression (75% of the control) (Fig. 2C),
indicating that the inhibition is highly sequence-speci¢c. A
direct visualization under a £uorescence microscope con¢rmed
the result from Western blot (Fig. 2D). A similar result was
obtained in 293A cells (data not shown). The U6^shLacZ
PCR product speci¢cally depressed LacZ expression in L929
cells (Fig. 2E) and 293A cells (not shown). A two-base mis-
match (U6^shLacZm) eliminated the RNAi e¡ect (Fig. 2E).
By counting LacZ-positive cells, we estimated that the LacZ
expression in the U6^shLacZ- and U^shLacZm-transfected
L929 cells were 9.5% and 109% of the control cells (U6^
shGFP-transfected cells), respectively.
We further tested whether U6^shDNAs constructed by
PCR work on endogenous genes. We chose annexin II, an
abundant Ca2þ-dependent, phospholipid/actin-binding protein
[29]. Two siRNA sequences speci¢cally targeted to mouse an-
nexin II were chosen from the mouse annexin II mRNA se-
Fig. 3. Inhibition of endogenous gene expression of annexin II by U6^shDNA PCR products. A: Sequence and putative folding of short hair-
pin oligonucleotides used to target the mouse annexin II gene. Note that there are one- or three-base mismatches in the target sequences of
mouse and human. B: The PCR products, U6^shAIIA and U6^shAIIB, were transfected into mouse L929 cells and human 293A cells for 48 h.
U6^shGL3 PCR products were used as a control. Annexin II was detected by Western blot. L-Actin was used as a loading control.
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quence (Fig. 3A). When the PCR products were transfected
into mouse L929 cells, we found that only U6^shAIIB re-
duced annexin II protein expression. However, U6^shAIIB
had little e¡ect in human 293 cells even though there is only
one base mismatch in the target sequences of mouse and hu-
man (Fig. 3B). After measurement by densitometry and nor-
malizing to L-actin, annexin II protein expression in U6^
shAIIB-treated mouse L929 cells and human 293A cells was
20% and 74% of the control (U6^shGL3-treated cells), respec-
tively. Another design of the annexin II siRNA sequence (U6^
shAIIA) did not inhibit annexin II protein expression in either
cell line (Fig. 3B). These results suggest that (i) U6^shDNA
PCR product can be used to reduce endogenous gene expres-
sion; (ii) the silencing is dependent on target sequences and is
highly speci¢c.
3.3. Inhibition of gene expression by CMV-shDNA PCR
products
Most of the vectors currently used for constructing shRNA
utilized an RNA polymerase III promoter, U6 or H1 [7,15,18^
22]. These promoters have a well-de¢ned termination site of
four or ¢ve consecutive thymidines and therefore are suitable
for the synthesis of small RNA in cells. A modi¢ed CMV
polymerase II promoter plus a minimal poly(A) cassette has
been used to synthesize shRNA [11,17]. We asked whether
PCR-based siRNA under the control of a RNA polymerase
II promoter could inhibit gene expression. Since the PCR
products only contain a promoter and shDNA, there is no
need for transcripts to be terminated with a transcriptional
termination signal at the 3P-end of the PCR products. How-
ever, to preserve some of the features of the siRNA de¢ned by
Tuschl and colleagues [2], six T were added at the 3P-end of
the PCR products. We used two designs in this experiment.
First, a strategy similar to the one used for the U6 promoter
was used (Fig. 4A). We ¢rst added a linker containing the
ApaI restriction site at the 3P-end of the CMV promoter. After
digestion with ApaI, we performed the ¢rst round of PCR
with a forward primer, 5P PCMVF, and a reverse primer,
3P Primer 1, containing (5P) a loop (9 nt)^antisense strand
(19 nt)^GGCC (3P) and the second round of PCR with the
Fig. 4. Inhibition of gene expression by CMV^shDNA PCR products. A: CMV^shDNAs were generated by two rounds of PCR using a for-
ward primer, 5P PCMVF, and two reverse primers, 3P Primer 1 (5P 7-nt loop^antisense strand^GGCC 3P) and 3P Primer 2 (5P poly(A)6^sense
strand^7-nt loop 3P). A linker containing an ApaI restriction site was added to the 3P-end of the CMV promoter. The ¢nal PCR products were
CMV^shDNA. B: Two PCR products containing CMV^sense strand (CMV^sDNA) and CMV^antisense strand (CMV^asDNA) were gener-
ated by one-step PCR using primer pairs: 5P PCMVF and 3P Primer A or B (5P antisense strand or sense strand^a sequence complementary to
the last 12 nt of the CMV promoter 3P), respectively. C: Two PCR products targeted to pGL3 were used for gene silencing: CMV^shGL3
(CMV-driven short hairpin DNA) and CMV^sGL3/CMV^asGL3 (CMV-driven sense strand or antisense strand of siRNA). The target sequence
for pGL3 is the same as in Fig. 2A. CMV^shGL3, CMV^sGL3, or CMV^sGL3/CMV^asGL3 were co-transfected for 24 h with pGL3 and
pRL plasmids into L929 cells. pUC18 plasmid was used as a control. pGL3 activity was normalized to pRL activity.
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5P PCMVF and another reverse primer, 3P Primer 2, containing
(5P) poly(A)6^sense strand (19 nt)^the 9-nt loop (3P). The ¢nal
PCR products contain the CMV promoter and shDNA fol-
lowed by T6. The second design was to generate siRNA from
two PCR products: CMV^sense strand^T6 and CMV^anti-
sense strand^T6, using the same forward primer, 5P PCMVF,
and a reverse primer containing A6, antisense or sense strand,
and a sequence complementary to the 3P-end of the CMV
promoter (3P Primer A or 3P Primer B) (Fig. 4B). We tested
the CMV-driven siRNA on L929 cells with co-transfection of
two reporter plasmids encoding pGL3 and pRL. The results
are shown in Fig. 4C. The CMV^shGL3 PCR product de-
pressed pGL3 activity by 92%. There is no quantitative di¡er-
ence between U6-driven shRNA and CMV-driven shRNA
products (compare Figs. 2B and 4C). While CMV^sense
strand of pGL3 siRNA (CMV^sGL3) had no e¡ect, co-trans-
fection of CMV^sense strand and CMV^antisense strand of
pGL3 siRNA (CMV^sGL3/CMV^asGL3) resulted in a 95%
inhibition of pGL3 activity. These results indicate that (i) the
CMV promoter is as e¡ective as the U6 promoter in the PCR-
based RNAi strategy. We speculate that other polymerase II
promoters could also be used in the PCR-based RNAi strat-
egy. It will be interesting to knock down gene expression using
cell- or tissue-speci¢c promoters based on this PCR method.
For example, to achieve cell-speci¢c expression, the SP-C pro-
moter can be chosen to target siRNA to alveolar epithelial
type II cells. (ii) The short hairpin structure is not essential for
the gene silencing, and sense strand and antisense strand can
be synthesized separately using the same promoter. However,
for future cloning purposes, the short hairpin design is pre-
ferred.
Castanotto et al. [30] recently reported an approach similar
to the present study. However, they only gave preliminary
qualitative results using a GFP reporter gene and a U6 pro-
moter. In the current study, we performed more detailed stud-
ies. (i) Three reporter genes (luciferase, GFP and LacZ) were
tested and quantitative results were given. (ii) We also dem-
onstrated that the PCR-based shRNA strategy also works on
an endogenous gene. (iii) In addition to the U6 promoter, we
showed that other promoters such as the CMV promoter can
be used to replace the U6 promoter. This is important because
potentially we can use this approach to screen tissue- or cell-
speci¢c promoter-driven shRNAs for tissue- or cell-speci¢c
targeting of siRNA.
In summary, we presented a rapid, easy and cheap PCR
method for screening shRNAs for functional studies. This
method is composed of two rounds of PCR using one univer-
sal primer (for all target genes) and two unique target se-
quence oligonucleotides. The PCR products provide DNA
templates containing a RNA polymerase promoter and a
short hairpin DNA or sense/antisense strand for in vivo syn-
thesis of siRNA in cells. The PCR products generated by this
method are highly e⁄cient and speci¢c. One- or two-base
mismatches eliminated gene silencing e¡ects. Depending on
the needs of future cloning, di¡erent promoters can be used.
Although we only tested two promoters, U6 and CMV, any
other promoters should be adapted for this method. Finally,
we suggest a general approach for using RNAi in a loss-
of-function study: (i) choose four or ¢ve siRNA sequences
from a target gene based on currently known rules (e.g.
http://www.mpibpc.gwdg.de/abteilungen/100/105/index.html);
(ii) test the e⁄ciency of selected sequences using the PCR
method developed in this study and choose the most e⁄cient
sequence for cloning; (iii) clone into an expression plasmid or
a virus vector; (iv) test on cells and animals for knocking
down the target gene and study phenotypic and functional
changes.
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